Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Sadif Analytics Prime
$25.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CEL-SCI Corp receives regulatory clearance to expand phase III head and neck cancer trial into Turkey


Tuesday, 22 Jul 2014 08:30am EDT 

CEL-SCI Corp:Says that Turkey's Ministry of Health has cleared the company to begin patient enrollment in CEL-SCI's global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).Expects to enroll patients through three clinical centers in Turkey.Turkey thus becomes the 16(th)country to participate in world's largest Phase III head and neck cancer trial.Head and neck cancer accounts for about 6 pct of all cancers, with about 600,000 new cases reported annually worldwide. CEL-SCI has received U.S. Orphan Drug designation for Multikine in head and neck cancer in the US.Further expansion of the Phase III trial is underway with a goal to have a total of 880 patients enrolled through about 100 clinical centers by the end of 2015.Over 220 patients have been enrolled in the study to date. 

Company Quote

0.52
-0.01 -1.89%
4:00pm EDT